Abstract
While an attractive target for treating a range of human diseases and conditions, signal transducer and activator of transcription 6 (STAT6) has resisted drug discovery efforts for decades. This Viewpoint summarizes the discovery of a highly potent, selective STAT6 degrader with minimal off-target activity.